Company news

Share this article:

GlaxoSmithKline and Tolerx, have announced a global collaboration deal worth up to $760 million to develop and commercialize otelixizumab (TRX4), a novel humanised anti-CD3 monoclonal antibody that has potential across a broad range of autoimmune and immune-mediated inflammatory diseases, including type 1 diabetes.

Pfizer and Taisho Pharmaceutical have signed a letter of intent for development and commercialization rights of Taisho's pre-clinical stage schizophrenia drug candidate TS-032 outside Japan.

Merck said it has been advised that the NDA for OTC Mevacor (lovastatin) will be reviewed by the FDA's Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee on Dec. 13. Merck is seeking approval of lovastatin 20 mg taken once daily to help lower cholesterol.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters